PlacidWay is pleased to announce a partnership in the global promotion of Beike Biotech, an international leader in stem cell treatment methodologies involving the cultivation, processing and storage of multiple types of stem cells.

Beike's mission is to "contribute toward new ideas and discoveries and formulate treatment protocols," states Biotech Chairman Dr. Sean Hu. "Researchers at Biotech have been trained internationally, including some of the best medical schools in the world such as those found in Sweden, Canada and Japan, and universities in the U.S. like Stanford, UCLA and the University of Minnesota."

Staff at Beike is truly an international group of experts from countries like the U.S., Great Britain, Romania, Africa, the Middle East and the Netherlands. Their goal is to create stem cell treatments and therapies that treat autism, cerebral palsy, and muscular dystrophy and spinal cord injuries, among others.

Specialty treatments at Beike include IV, lumbar puncture or CT-guided stem cell implants or injections at facilities in mid-and southeastern China, including Shanghai and Guangdong. Beike utilizes and focuses research on umbilical cord blood derived stem cells and autologous bone marrow stem cells collected from the patient himself. Treatments average 25 to 40 days, depending on treatment approach and medical condition of the patient.

Care at Beike
Beike Biotech offers continuous care throughout the stem cell therapy process, as well as aftercare following the patient's return to his home country. Follow-up care lasts 12 months following a complete health evaluation and discharge, and the services of a health care coordinator available to answer post-treatment questions or concerns.

Beike has provided for excellence in treatments and advancements in stem cell research and technology, including their partnerships with leading stem cell research, facilities around the globe, including Thermo Genesis Corporation, based in the U.S. Beike uses only cutting-edge stem cell storage and processing methods in adult stem cell collection, processing methodologies and archiving platforms.

"PlacidWay is extremely pleased to promote opportunities for international travelers to the best in advanced medical treatment and hope through stem cell research and therapies," says Pramod Goel, CEO and founder of PlacidWay. "Regardless of origin, everyone deserves the best in health care options and opportunities. PlacidWay is pleased to include Beike Biotech to our growing database of highly trained experts in the field of stem cell technologies to ensure that medical care is accessible to everyone."

Chairman Dr. Sean Hu and CSO Dr. Susan Jiang are highly trained and experienced in biotechnology research and fields of study. Dr. Hu received his Ph.D. from the Department of Biochemistry and Biophysics at the Gothenburg University in Sweden and Dr. Jiang received her post-doctoral work from the Physiology Department at the University of Arkansas. Dr. Jiang also participated in high-tech treatments utilizing stem cell treatment potential for neonatal respiratory disease conditions as well as creating numerous wound-healing treatments and methods utilizing stem cell technologies. is a health and wellness tourism company, combining affordable healthcare with exotic travel options. is designed for those who place a premium on their quality of life. Whether you have a physiological need requiring medical attention, a social motivation to change the way you look, or an inherent desire to seek self actualization through organic, holistic, and healthy healthcare options, provides enormous options. At, you are presented with the very best providers of health and wellness, from around the world. The choice is entirely yours! You are given a complete freedom to choose your own treatment at a medical center, and in a country of your choice. If you need to visit this hospital then feel free here: 1.303.578.0719 or

Author's Bio: 

A, Beike Biotech, is a Chinese biotechnology company with main offices in Shenzhen and Taizhou. Beike’s, stem cell research, and clinical applications were developed in the early 1990s.